PR93359

SHANGHAI, Nov. 30, 2021 /PRNewswire=KYODO JBN/ --

Jemincare, a leading pharmaceutical company from China, announced today its

wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd.,

had licensed exclusive worldwide ex-China rights to the Kras inhibitor,

JMKX1899, to HUYABIO International, the leader in accelerating global

development of China's pharmaceutical innovations. Jemincare will retain the

relevant rights in greater China area.

Kras is one of the most mutated oncogenes in human cancers. The prevalent G12C

mutation drives tumor growth and metastasis and has become an important

validated target for therapy especially in lung and colorectal cancer.

Targeting the GTP pocket of Kras in the switch-II region, which has made Kras

druggable, enables the development of more potent and potentially effective

inhibitors.  

JMKX1899 is a KRAS inhibitor independently developed by Jemincare. Data from

preclinical studies shows it has strong blood-brain-barrier crossing capability

and has no risk of hERG inhibition and drug-drug-interaction. Jemincare has

filed the IND to NMPA in Oct. 2021. The parties will work closely to file IND

in US FDA in 2021 to move towards clinical development.

Mr. Hong Liang, President of Jemincare Pharmaceutical Group, said, "We are

delighted to work with HUYABIO to explore global development of this unique

KRAS inhibitor. This is our first new chemical entity program out-licensed to a

global partner. HUYABIO has generated a lot of experience to bring innovative

drugs from China to global market. We look forward to generating the clinical

efficacy and safety data from global clinical trial since the candidate has

huge potential to fill strong unmet needs."

Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO, said, "We are excited

to have added the clinical stage Kras inhibitor to our oncology pipeline

especially to test in combination with our SHP inhibitor against a variety of

solid tumors. We're delighted to have an excellent partner Jemincare to

co-develop combinations that can benefit patients worldwide."

About HUYABIO International

HUYABIO™ is the leader in accelerating the global development of novel

biopharmaceutical product opportunities originating in China enabling faster,

more cost-effective and lower-risk drug development in the global markets.

Through extensive collaboration with biopharmaceutical, academic and commercial

organizations, it has built the largest China-sourced compound portfolio

covering all therapeutic areas. Hiyasta® the company's first commercial product

is marketed in Japan. With offices in the US, Japan, South Korea, Canada,

Ireland and eight strategic locations across China, the Company has become a

partner of choice to accelerate product development and maximize value

globally. For more information, please visit www.huyabio.com.

About Jemincare

Shanghai Jemincare Pharmaceutical Co., Ltd was established in 2018 as the R&D

center of Jiangxi Jemincare Group Co., Ltd. Shanghai Jemincare now has

developed into a strong team with around 500 scientists comprised by 3

innovation centers, Small Molecule Innovative Center, Biologics Innovation

Center and Technology Innovation Center. JMKX1899 is developed by the Small

Molecule Innovation Center which has 10 programs entering IND or IND-enabling

stage and 2 programs entering clinical stage.

Jiangxi Jemincare Group Co., Ltd. is a leading pharmaceutical company from

China. Founded in 1999, Jemincare group has over 10,000 employees dedicated to

the development, manufacturing and commercialization of therapeutics in its

strategic fields including oncology, nephrology, cerebro-cardiovascular,

anti-infection, analgesic, respiratory and Pediatrics. For more information,

please visit www.jemincare.com, or email PR@jemincare.com.

SOURCE  Jemincare

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=409301

   Caption: Jemincare